1887

Abstract

No longitudinal molecular epidemiology of parechovirus A3 (PeV-A3) over a decade is available and PeV-A3-associated myalgia/myositis has been reported only in Japan. Thus, we aimed to clarify the longitudinal molecular epidemiology of PeV-A3 with a major focus on the strains detected from PeV-A3-associated myalgia/myositis cases. We performed sequence and phylogenetic analysis for the VP1 region of PeV-A3 strains in Yamagata, Japan, between 2003 and 2016. The phylogenetic analysis indicated that PeV-A3 strains caused PeV-A3-associated myalgia/myositis as well as a variety of infectious diseases, ranging from mild to severe, in subjects ranging from neonates to adults, irrespective of genetic cluster or variations. PeV-A3 strains are causative agents of a variety of human diseases, irrespective of their genetic cluster. Furthermore, we consider that PeV-A3-associated myalgia/myositis may occur, not only in Japan, but also in other countries, as closely related PeV-A3 strains have been circulating around the world.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000894
2018-12-17
2020-01-27
Loading full text...

Full text loading...

/deliver/fulltext/jmm/68/3/424.html?itemId=/content/journal/jmm/10.1099/jmm.0.000894&mimeType=html&fmt=ahah

References

  1. Romero JR, Modlin JF. Human parechoviruses. In Blaser MJ. (editor) Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th ed. Philadelphia: Saunders Elsvier; 2015; pp.2091–2094
    [Google Scholar]
  2. Pallansch MA, Oberste MS, Whitton JL. Enteroviruses: polioviruses, coxsackieviruses echoviruses, and newer enteroviruses. In Knipe DM, Howley PM. (editors) Fields’s Virology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013; pp.490–530
    [Google Scholar]
  3. Ito M, Yamashita T, Tsuzuki H, Takeda N, Sakae K. Isolation and identification of a novel human parechovirus. J Gen Virol 2004;85:391–398 [CrossRef][PubMed]
    [Google Scholar]
  4. Harvala H, Simmonds P. Human parechoviruses: biology, epidemiology and clinical significance. J Clin Virol 2009;45:1–9 [CrossRef][PubMed]
    [Google Scholar]
  5. Esposito S, Rahamat-Langendoen J, Ascolese B, Senatore L, Castellazzi L et al. Pediatric parechovirus infections. J Clin Virol 2014;60:84–89 [CrossRef][PubMed]
    [Google Scholar]
  6. Ito M, Yamashita T, Tsuzuki H, Kabashima Y, Hasegawa A et al. Detection of human parechoviruses from clinical stool samples in Aichi, Japan. J Clin Microbiol 2010;48:2683–2688 [CrossRef][PubMed]
    [Google Scholar]
  7. van der Sanden S, de Bruin E, Vennema H, Swanink C, Koopmans M et al. Prevalence of human parechovirus in the Netherlands in 2000 to 2007. J Clin Microbiol 2008;46:2884–2889 [CrossRef][PubMed]
    [Google Scholar]
  8. Harvala H, Robertson I, Chieochansin T, Mcwilliam Leitch EC, Templeton K et al. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. J Infect Dis 2009;199:1753–1760 [CrossRef][PubMed]
    [Google Scholar]
  9. Aizawa Y, Suzuki Y, Watanabe K, Oishi T, Saitoh A. Clinical utility of serum samples for human parechovirus type 3 infection in neonates and young infants: The 2014 epidemic in Japan. J Infect 2016;72:223–232 [CrossRef][PubMed]
    [Google Scholar]
  10. Schuffenecker I, Javouhey E, Gillet Y, Kugener B, Billaud G et al. Human parechovirus infections, Lyon, France, 2008-10: evidence for severe cases. J Clin Virol 2012;54:337–341 [CrossRef][PubMed]
    [Google Scholar]
  11. Nelson TM, Vuillermin P, Hodge J, Druce J, Williams DT et al. An outbreak of severe infections among Australian infants caused by a novel recombinant strain of human parechovirus type 3. Sci Rep 2017;7:44423 [CrossRef][PubMed]
    [Google Scholar]
  12. Sharp J, Harrison CJ, Puckett K, Selvaraju SB, Penaranda S et al. Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations. Pediatr Infect Dis J 2013;32:213–216 [CrossRef][PubMed]
    [Google Scholar]
  13. Pham NT, Trinh QD, Khamrin P, Maneekarn N, Shimizu H et al. Diversity of human parechoviruses isolated from stool samples collected from Thai children with acute gastroenteritis. J Clin Microbiol 2010;48:115–119 [CrossRef][PubMed]
    [Google Scholar]
  14. Huang YP, Hsieh JY, Wu HS, Yang JY. Molecular and epidemiological study of human parechovirus infections in Taiwan, 2007-2012. J Microbiol Immunol Infect 2016;49:321–328 [CrossRef][PubMed]
    [Google Scholar]
  15. Tanaka S, Aoki Y, Matoba Y, Yahagi K, Itagaki T et al. Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014. Microbiol Immunol 2016;60:854–858 [CrossRef][PubMed]
    [Google Scholar]
  16. Mizuta K, Kuroda M, Kurimura M, Yahata Y, Sekizuka T et al. Aoki Y, Ikeda T, Abiko C, Noda M, Kimura H, Mizutani T, Kato T, Kawanami T, Ahiko T. Epidemic myalgia in adults associated with human parechovirus type 3 infection, Yamagata, Japan, 2008. Emerg Infect Dis 2012;18:1787–1793
    [Google Scholar]
  17. Mizuta K, Yamakawa T, Nagasawa H, Itagaki T, Katsushima F et al. Epidemic myalgia associated with human parechovirus type 3 infection among adults occurs during an outbreak among children: findings from Yamagata, Japan, in 2011. J Clin Virol 2013;58:188–193 [CrossRef][PubMed]
    [Google Scholar]
  18. Mizuta K, Yamakawa T, Kurokawa K, Chikaoka S, Shimizu Y et al. Epidemic myalgia and myositis associated with human parechovirus type 3 infections occur not only in adults but also in children: findings in Yamagata, Japan, 2014. Epidemiol Infect 2016;144:1286–1290 [CrossRef][PubMed]
    [Google Scholar]
  19. Yamakawa T, Mizuta K, Kurokawa K, Nagasawa H, Yamada T et al. Clinical characteristics of 17 adult patients with epidemic myalgia associated with human parechovirus type 3 infection. Rinsho Shinkeigaku 2017;57:485–491 [CrossRef][PubMed]
    [Google Scholar]
  20. Kurimura M, Mizuta K, Yamakawa T, Kato T. HPeV3-associated myalgia/myositis: Epidemic myalgia as an emerging infectious disease. Neurol Med 2017;86:307–314
    [Google Scholar]
  21. Yamamoto SP, Kaida A, Naito T, Hosaka T, Miyazato Y et al. Human parechovirus infections and child myositis cases associated with genotype 3 in Osaka City, Japan, 2014. J Med Microbiol 2015;64:1415–1424 [CrossRef][PubMed]
    [Google Scholar]
  22. Shinomoto M, Kawasaki T, Sugahara T, Nakata K, Kotani T et al. Yoshitake H, Yuasa K, Saeki M, Fujiwara Y. First report of human parechovirus type 3 infection in a pregnant woman. Int J Infect Dis 2017;59:22–24
    [Google Scholar]
  23. Tanaka S, Kunishi Y, Ota M, Ono A, Kanno N et al. Kurakami Y, Yanagibashi T, Matsubayashi M, Hao Y, Iwabuchi K, Oshita F, Yoshie K, Kato Y. Severe human parechovirus type 3 infection in adults associated with gastroenteritis in their children. Infect Dis 2017;49:772–774
    [Google Scholar]
  24. Matsuuchi S, Abe A, Daitsu T, Maeda S, Shimizu Y. Clinical characteristics of human parechovirus 3 infection in seven neonates and infants. J Pediatr Infect Dis Immunol 2018;30:19–25
    [Google Scholar]
  25. National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare Weekly detection of human parechovirus type 3 in 2013 and 2014, Japan. Infectious Agents Surveillance Reporthttp://www.nih.go.jp/niid/images/iasr/arc/ot/2014/data2014.84j.pdf Accessed 25th February 2016
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000894
Loading
/content/journal/jmm/10.1099/jmm.0.000894
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error